Data Article

Dataset on chemotherapy-induced nausea and vomiting (CINV) and quality of life (QOL) during multiple chemotherapy cycles among a Chinese breast cancer patient population who were randomized to antiemetic regimens with or without olanzapine

Winnie Yeo a,b,∗, Vicky T.C. Chan a, Leung Li a, Thomas K.H. Lau a, Kwai Tung Lai a, Elizabeth Pang a, Maggie Cheung a, Frankie K.F. Mo a

a Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR
b Hong Kong Cancer Institute, State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong SAR

ARTICLE INFO

Article history:
Received 12 February 2020
Revised 4 March 2020
Accepted 5 March 2020
Available online 12 March 2020

Keywords:
Cytotoxic treatment
Multiple cycles
Doxorubicin
Adriamycin
Cyclophosphamide
Quality of life (QOL)
Chemotherapy-induced nausea and vomiting (CINV)
Asians

ABSTRACT

Chemotherapy-induced nausea and vomiting (CINV) are highly distressing symptoms for cancer patients undergoing cytotoxic chemotherapy. This dataset was obtained from a homogenous group of Chinese breast cancer patients who were uniformly planned to receive a highly emetogenic (neo)adjuvant chemotherapy regimen, consisting of doxorubicin and cyclophosphamide (commonly known as AC). Patients were being randomized to one of the two antiemetic regimens: aprepitant, ondansetron and dexamethasone with (the Olanzapine arm) or without olanzapine (the Standard arm). Patients underwent self-reported diaries and questionnaires to record their nausea and vomiting symptoms, use of rescue medication as well as their quality of life (QOL). The primary and secondary endpoints have focused on efficacy

∗ Corresponding author at: Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR.
E-mail address: winniedyoe@cuhk.edu.hk (W. Yeo).

https://doi.org/10.1016/j.dib.2020.105421
2352-3409/© 2020 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
Analysis during the first cycle of AC chemotherapy; the results have been reported in The Breast [1]. In this Data in Brief article, we provide outcome of the analysis of data collected during multiple cycles of chemotherapy. The data reported here include the proportion of patients with “Complete Response”, “Complete Protection” and “Total Control” of emesis in the acute (0–24 h), delayed (24–120 h) and overall periods (0–120 h), as well as QOL data during all the 4 cycles of AC.

© 2020 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Specifications table

| Subject | Oncology; | Chemotherapy |
|---------|-----------|--------------|
| Specific subject area | Tables and Functional Living Index- Emesis (FLIE) Questionnaire (https://eprovide.mapi-trust.org/instruments/functional-living-index-emesis#need_this_questionnaire) | |
| Type of data | Raw | Analyzed | Filtered |
| How data were acquired | Patients’ diaries and questionnaires to capture incidence and severity of CINV and use of rescue medication, Functional Living Index- Emesis (FLIE) questionnaire to capture patients’ QOL during chemotherapy. The diaries and questionnaires were filled in by individual patient at a university affiliated hospital and at their homes. | |
| Parameters for data collection | All patients were planned for 4 cycles of AC chemotherapy. Prior to each cycle of chemotherapy on Day 1, individual patient filled in self-administered FLIE questionnaire. A diary was given to each patient to bring home, so that she could record the date and time of any vomiting episodes and the use of rescue medication following the chemotherapy infusion for 120 h. Within the diary, there were also nausea ratings (by visual analogue scale, VAS; 0 mm implied no nausea; 100 mm implied nausea that was “as bad as it could be”); on days 2 to 6, each patient rated the symptoms of nausea for the preceding 24 h using the VAS. After patients had completed the diary in the morning of day 6, they immediately completed the FLIE questionnaire again. | |
| Description of data collection | Prospective cohort of 120 adult women with breast cancer who were randomly assigned to one of the two antiemetic regimens prior to their chemotherapy. They were asked to fill in self-reported diaries and Functional Living Index- Emesis (FLIE) Questionnaire (https://eprovide.mapi-trust.org/instruments/functional-living-index-emesis#need_this_questionnaire) | |
| Data source location | Institution: Comprehensive Cancer Trials Unit, Department of Clinical Oncology, Faculty of Medicine, The Chinese University of Hong Kong City/Town/Region: Hong Kong Country: China | |
| Data accessibility | With the article | |
| Related research article | Author’s name: Winnie Yeo, Thomas KH Lau, Leung Li, Kwai Tung Lai, Elizabeth Pang, Maggie Cheung, Vicky TC Chan, Ashley Wong, Winnie MT Soo, Vanessa TY Yeung, Teresa Tse, Daisy CM Lam, Eva WM Yeung, Kim PK Ng, Nelson LS Tang, Macy Tong, Joyce JS Suen, Frankie KF Mo. Title: A Randomized Study of Olanzapine-containing versus Standard Antiemetic Regimens for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese breast cancer patients Journal: The Breast DOI: 10.1016/j.breast.2020.01.005. | |
Value of the data

- These data over multiple cycles of chemotherapy are important for understanding and interpretations of the potential benefits of new antiemetic agents in the control of CINV [1].
- Clinicians and researchers working in the fields of oncology, palliative care and general practice may benefit from these data.
- The full description of the results provides deeper insights regarding efficacy of different antiemetic regimens when they are administered to cancer patients undergoing highly emetogenic chemotherapy.
- While data during the first chemotherapy cycle are often the primary endpoints and are thus invariably reported, data on subsequent chemotherapy cycles are rarely reported in the literature. These data provide a unique opportunity to follow symptoms and QOL of women with breast cancer who underwent 4 cycles of highly emetogenic AC chemotherapy.

1. Data description

In this Data in Brief article, we first provide the comparison of Complete Response (Table 1a and b), Complete Protection (Table 2a and b) and Total Control (Table 3a and b) of CINV during the acute period, delayed period and overall period across the 4 cycles of chemotherapy among patients who were randomized to one of the two study arms. The raw data based on which analyses were conducted for Complete Response, Complete Protection and Total Control are available in Supplementary File S1, Supplementary File S2 and Supplementary File S3 respectively.

In summary, there was no difference on Complete Response, Complete Protection and Total Control across the four cycles in the Olanzapine arm. However, in the Standard arm, some differences were observed in Complete Response, Complete Protection and Total Control when comparing cycle 1 with other cycles.

We also provide data on QOL data in the overall period during the 4 cycles of chemotherapy in the two study arms. The raw data are available in Supplementary File S4. Based on the data, differences were only detected between the 2 study arms in cycle 1.

Table 1
Proportion of patients with Complete Response (CR) during the acute period, delayed and overall time frames across the 4 cycles.

| Comparison | Overall Time frame | Acute | Delayed |
|------------|--------------------|-------|---------|
|            | CR rate | CR rate | p-value | CR rate | CR rate | p-value | CR rate | CR rate | p-value |
| a) Olanzapine arm |        |        |        |        |        |        |        |        |        |
| C1 vs C2   | 65.0    | 70.2    | 0.5502 | 70.0    | 79.0    | 0.2679 | 92.9    | 88.9    | 0.5221 |
| C2 vs C3   | 70.2    | 75.0    | 0.5655 | 79.0    | 82.1    | 0.6680 | 88.9    | 91.3    | 0.6996 |
| C3 vs C4   | 75.0    | 73.7    | 0.8728 | 82.1    | 82.5    | 0.9652 | 91.3    | 89.4    | 0.7514 |
| C1 vs C3   | 65.0    | 75.0    | 0.2410 | 70.0    | 82.1    | 0.1267 | 92.9    | 91.3    | 0.7880 |
| C1 vs C4   | 65.0    | 73.7    | 0.3090 | 70.0    | 82.5    | 0.1145 | 92.9    | 89.4    | 0.5649 |
| C2 vs C4   | 70.2    | 73.7    | 0.6768 | 79.0    | 82.5    | 0.6350 | 88.9    | 89.4    | 0.9419 |
| b) Standard arm |        |        |        |        |        |        |        |        |        |
| C1 vs C2   | 38.3    | 57.6    | 0.0352 | 51.7    | 66.1    | 0.1097 | 74.2    | 87.2    | 0.1652 |
| C2 vs C3   | 57.6    | 57.6    | 1.0000 | 66.1    | 66.1    | 1.0000 | 87.2    | 87.2    | 1.0000 |
| C3 vs C4   | 57.6    | 57.6    | 1.0000 | 66.1    | 71.2    | 0.5517 | 87.2    | 81.0    | 0.4455 |
| C1 vs C3   | 38.3    | 57.6    | 0.0352 | 51.7    | 66.1    | 0.1097 | 74.2    | 87.2    | 0.1652 |
| C1 vs C4   | 38.3    | 57.6    | 0.0352 | 51.7    | 71.2    | 0.0288 | 74.2    | 81.0    | 0.4902 |
| C2 vs C4   | 57.6    | 57.6    | 1.0000 | 66.1    | 71.2    | 0.5517 | 87.2    | 81.0    | 0.4455 |
Table 2
Proportion of patients with Complete Protection (CP) during the acute period, delayed period and overall time frames across the 4 cycles.

| Comparison   | Overall Time frame | Acute | Delayed |   |
|--------------|--------------------|-------|---------|---|
|              | CP rate            | CP rate | p-value | CP rate | CP rate | p-value | CP rate | CR rate | p-value |
| a) Olanzapine arm |                   |       |         |         |         |         |         |         |         |
| C1 vs C2     | 61.7               | 64.9   | 0.7159  | 70.0    | 73.7    | 0.6580  | 88.1    | 88.1    | 1.0000  |
| C2 vs C3     | 64.9               | 67.9   | 0.7404  | 73.7    | 76.8    | 0.7026  | 88.1    | 88.4    | 0.9684  |
| C3 vs C4     | 67.9               | 68.4   | 0.9487  | 76.8    | 77.2    | 0.9590  | 88.4    | 88.6    | 0.9692  |
| C1 vs C3     | 61.7               | 67.9   | 0.4858  | 70.0    | 76.8    | 0.4092  | 88.1    | 88.4    | 0.9684  |
| C1 vs C4     | 61.7               | 68.4   | 0.4440  | 70.0    | 77.2    | 0.3782  | 88.1    | 88.6    | 0.9376  |
| C2 vs C4     | 64.9               | 68.4   | 0.6911  | 73.7    | 77.2    | 0.6634  | 88.1    | 88.6    | 0.9376  |
| b) Standard arm |                 |       |         |         |         |         |         |         |         |
| C1 vs C2     | 36.7               | 55.9   | 0.0351  | 50.0    | 64.1    | 0.1123  | 73.3    | 86.8    | 0.1595  |
| C2 vs C3     | 55.9               | 54.2   | 0.8532  | 64.1    | 64.1    | 1.0000  | 86.8    | 84.2    | 0.7444  |
| C3 vs C4     | 54.2               | 52.5   | 0.8536  | 64.1    | 66.1    | 0.8467  | 84.2    | 79.5    | 0.5911  |
| C1 vs C3     | 36.7               | 54.2   | 0.0542  | 50.0    | 64.1    | 0.1123  | 73.3    | 84.2    | 0.2707  |
| C1 vs C4     | 36.7               | 52.5   | 0.0815  | 50.0    | 66.1    | 0.0752  | 73.3    | 79.5    | 0.5482  |
| C2 vs C4     | 55.9               | 52.5   | 0.7117  | 64.1    | 66.1    | 0.8467  | 86.8    | 79.5    | 0.3890  |

Table 3
Proportion of patients with Total Control (TC) during the acute period, delayed period and overall time frames across the 4 cycles.

| Comparison   | Overall Time frame | Acute | Delayed |   |
|--------------|--------------------|-------|---------|---|
|              | TC rate            | TC rate | p-value | TC rate | TC rate | p-value | TC rate | TC rate | p-value |
| a) Olanzapine arm |                   |       |         |         |         |         |         |         |         |
| C1 vs C2     | 51.7               | 50.9   | 0.9319  | 65.0    | 59.6    | 0.5504  | 79.5    | 85.3    | 0.5177  |
| C2 vs C3     | 50.9               | 55.4   | 0.6333  | 59.6    | 66.1    | 0.4800  | 85.3    | 83.8    | 0.8605  |
| C3 vs C4     | 55.4               | 54.4   | 0.9174  | 66.1    | 63.2    | 0.7461  | 83.8    | 86.1    | 0.7811  |
| C1 vs C3     | 51.7               | 55.4   | 0.6905  | 65.0    | 66.1    | 0.9034  | 79.5    | 83.8    | 0.6291  |
| C1 vs C4     | 51.7               | 54.4   | 0.7683  | 65.0    | 63.2    | 0.8355  | 79.5    | 86.1    | 0.4490  |
| C2 vs C4     | 50.9               | 54.4   | 0.7075  | 59.6    | 63.2    | 0.7004  | 85.3    | 86.1    | 0.9222  |
| b) Standard arm |                 |       |         |         |         |         |         |         |         |
| C1 vs C2     | 26.7               | 45.8   | 0.0302  | 41.7    | 57.6    | 0.0817  | 64.0    | 79.4    | 0.1882  |
| C2 vs C3     | 45.8               | 45.8   | 1.0000  | 57.6    | 57.6    | 1.0000  | 79.4    | 79.4    | 1.0000  |
| C3 vs C4     | 45.8               | 47.5   | 0.8536  | 57.6    | 59.3    | 0.8518  | 79.4    | 80.0    | 0.9516  |
| C1 vs C3     | 26.7               | 45.8   | 0.0302  | 41.7    | 57.6    | 0.0817  | 64.0    | 79.4    | 0.1882  |
| C1 vs C4     | 26.7               | 47.5   | 0.0188  | 41.7    | 59.3    | 0.0541  | 64.0    | 80.0    | 0.1671  |
| C2 vs C4     | 45.8               | 47.5   | 0.8536  | 57.6    | 59.3    | 0.8518  | 79.4    | 80.0    | 0.9516  |

2. Experimental design, materials, and methods

The original study consisted of a homogenous group of Chinese breast cancer patients who were uniformly planned to receive (neo)adjuvant AC chemotherapy. Patients were being randomized to one of the two antiemetic regimens: aprepitant, ondansetron and dexamethasone with or without olanzapine.

Between the two study arms, the primary objective was to compare the antiemetic efficacies in the first cycle of AC. The secondary objectives were to compare QOL in the first cycle of AC and to compare the tolerability and efficacy of the study treatments.

All patients were planned for 4 cycles of AC chemotherapy. Data collected included patients’ baseline characteristics. In addition to cycle 1, patients’ symptoms and QOL were captured during 2nd–4th cycle of chemotherapy. Individual patient filled in self-administered FLIE questionnaire on day 1 before AC chemotherapy. After chemotherapy, the patients went home with the provision of a diary. Each patient recorded the date and time of any vomiting episodes and the use of rescue medication in the first 120 h after AC chemotherapy. On days 2 to 6, each patient rated
the symptoms of nausea for the preceding 24 h using the VAS in the diary. After patients had completed the diary in the morning of day 6, they immediately completed the FLIE questionnaire again.

The primary and secondary study outcomes related to outcomes in cycle 1 have been reported [1]. In this Data in Brief article, we provide outcome of the analysis of data collected during multiple cycles of AC. Three time-frames were assessed during each AC chemotherapy cycle; assessments started from the initiation of AC chemotherapy infusion (0 h) up to beginning of day 6 (~120 h). “Acute” period referred to 0–24 h after the initiation of AC, “delayed” period referred to 24–120 h, while “overall” period referred to 0–120 h The variables measured were the proportion of patients with “Complete Response”, “Complete Protection” and “Total Control”, definitions of which have been provided in the original report [1] as well as previous studies [2–4]. These assessments were done primarily over the “overall” period, and were also conducted separately during “acute” and “delayed” periods of each chemotherapy cycle. QOL data was collected during the overall period of each chemotherapy cycle.

For efficacy analyses over multiple cycles, “Complete Response”, “Complete Protection”, and “Total Control” over multiple cycles in the acute (0–24 h), delayed (24–120 h) and overall periods (0–120 h) were assessed using chi-square test for dichotomous data. For the analysis of the FLIE questionnaire, the nausea domain, vomiting domain and total score (the sum of the two domains) in the overall period were compared between the two arms using Wilcoxon Rank Sum test for continuous data.

Acknowledgments

This study was funded by Madam Diana Hon Fun Kong Donation for Cancer Research (Grant number: CUHK Project Code 7104870). The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. WY reports consultancy/advisory roles and receipt of personal fees for Novartis, Pfizer, AstraZeneca, Eli Lilly, Roche, Mundipharma and Amgen.

Conflict of Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.dib.2020.105421.

References

[1] W. Yeo, T.K.H. Lau, L. Li, K.T. Lai, E. Pang, M. Cheung, V.T.C. Chan, A. Wong, W.M.T. Soo, V.T.Y. Yeung, T. Tse, D.C.M. Lam, E.W.M. Yeung, K.P.K. Ng, N.L.S. Tang, M. Tong, J.J.S. Suen, E.K.F. Mo, A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients, Breast 50 (2020), doi:10.1016/j.breast.2020.01.005.

[2] W. Yeo W, F.K. Mo, J.J. Suen, W.M. Ho, S.L. Chan, W. Lau, J. Koh, W.K. Yeung, W.H. Kwan, K.K. Lee, T.S. Mok, A.N. Poon, K.C. Lam, E.K. Hui, B. Zee, A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy, Breast Cancer Res. Treat. 113 (2009), doi:10.1007/s10549-008-9957-9.
[3] R.M. Navari, R. Qin, K.J. Ruddy, H. Liu, S.F. Powell, M. Bajaj, L. Dietrich, D. Biggs, J.M. Lafey, C.L. Loprinzi, Olanzapine for chemotherapy-induced nausea and vomiting, N. Engl. J. Med. 375 (2016), doi:10.1056/NEJMoa1515725.

[4] P.J. Hesketh, G. Rossi, G. Rizzi, M. Palmas, A. Alyasova, I. Bondarenko, A. Lisysnksaya, R.J. Gralits, Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study, Ann. Oncol. 25 (2014), doi:10.1093/annonc/mdu110.